Location History:
- Frederiksberg C, DK (2012)
- Frederiksberg, DK (2015 - 2017)
Company Filing History:
3 out of 1,371 
3 out of 384 
Years Active: 2012-2017
Title: Nina Lundin: Innovator in Lipase Variants for Pharmaceutical Use
Introduction
Nina Lundin is a notable inventor based in Denmark, recognized for her contributions to the field of pharmaceuticals. She has focused her research on lipase variants that have significant medical applications. Although she currently holds no patents, her work has the potential to impact various digestive disorders.
Latest Patents
Lundin's latest invention involves lipase variants related to the Thermomyces lanuginosus lipase. This invention comprises amino acids 1-269 of SEQ ID NO: 2, and it may be used in combination with a protease and/or an amylase. The medical indications for her work include the treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, and both type I and type II diabetes. The lipases she has developed demonstrate improved digestion performance in vitro, enhanced activity at neutral pH, and stability against protease degradation, as well as in the presence of pepsin and bile salts. Additionally, her invention includes methods for determining the digestion performance of lipases in vitro.
Career Highlights
Throughout her career, Nina Lundin has worked with prominent companies such as Novozymes, Inc. and Novozymes A/S. Her experience in these organizations has contributed to her expertise in the field of enzymatic research and development.
Collaborations
Lundin has collaborated with notable colleagues, including Allan Svendsen and Michael Skjoet. These partnerships have likely enriched her research and innovation efforts.
Conclusion
Nina Lundin is an innovative inventor whose work on lipase variants holds promise for advancing pharmaceutical treatments for digestive disorders. Her contributions to the field reflect her dedication to improving health outcomes through scientific research.